Home   »   DAE and IDRS Labs Collaborate On...

DAE and IDRS Labs Collaborate On Aktocyte Tablets For Cancer

 

In a landmark collaboration, scientists from the Department of Atomic Energy (DAE) and Bengaluru-based IDRS Labs have united their expertise to develop Aktocyte tablets for the treatment of pelvic cancer. The tablets, designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator, and antioxidant, mark a significant advancement in cancer care, according to a statement from the DAE.

Collaboration for Progress

Experts from the Bhabha Atomic Research Centre in Mumbai, Tata Memorial Hospital in Mumbai, and the Advanced Centre for Training Research and Education in Cancer in Navi Mumbai have joined forces with IDRS Labs in this pioneering project. The collaboration reflects a synergy of knowledge and resources from leading institutions, combining their strengths to address the challenges posed by pelvic cancer treatment, specifically focusing on minimizing the side effects associated with radiotherapy.

Aim: Minimizing Radiotherapy Side Effects

The primary aim of this collaborative effort is to minimize the side effects of radiotherapy, a crucial aspect of cancer treatment. Radiotherapy is a common therapeutic approach, but it often comes with significant side effects that impact patients’ quality of life. By developing Aktocyte tablets as an adjuvant to cancer radiotherapy, the researchers aim to enhance the treatment’s efficacy while reducing its adverse effects.

Innovative Features of Aktocyte Tablets

Aktocyte tablets have been designed with multiple functions, making them a versatile addition to cancer treatment. Acting as a regenerative nutraceutical, the tablets aim to support the body’s natural healing processes. Additionally, they function as immunomodulators, enhancing the body’s immune response to cancer cells. The antioxidant properties of Aktocyte further contribute to protecting healthy cells from damage during the course of radiotherapy.

Approval from FSSAI

The significance of Aktocyte in cancer care is further underscored by its approval from the Food Safety and Standards Authority of India (FSSAI). This regulatory approval ensures that the tablets meet the necessary safety and quality standards, providing confidence in their use as a part of cancer treatment protocols.

Revolutionizing Pelvic Cancer Care

Aktocyte tablets offer a promising solution for treating pelvic cancer, with their multifunctional properties and the backing of regulatory approval. This innovative approach not only aims to enhance the effectiveness of radiotherapy but also prioritizes the well-being of patients by minimizing treatment-related side effects.

Important Questions Related to Exams

Q. Which institutions are actively involved in this collaborative effort?

Answer: The collaboration includes scientists from the Bhabha Atomic Research Centre, Tata Memorial Hospital in Mumbai, and the Advanced Centre for Training Research and Education in Cancer in Navi Mumbai, in addition to Bengaluru-based IDRS Labs.

Q. What role do Aktocyte tablets play in cancer treatment?

Answer: Aktocyte tablets serve as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator, and antioxidant, collectively aiming to advance the field of cancer care.

Q. Why is minimizing side effects particularly crucial in cancer radiotherapy?

Answer: Minimizing side effects is crucial in cancer radiotherapy to improve patients’ quality of life during and after treatment, ensuring a more positive overall experience.

DAE and IDRS Labs Collaborate On Aktocyte Tablets For Cancer_40.1

DAE and IDRS Labs Collaborate On Aktocyte Tablets For Cancer_50.1

TOPICS: